PMID- 35013090
OWN - NLM
STAT- MEDLINE
DCOM- 20220314
LR  - 20220314
IS  - 1643-3750 (Electronic)
IS  - 1234-1010 (Print)
IS  - 1234-1010 (Linking)
VI  - 28
DP  - 2022 Jan 11
TI  - Association Between Hyperhomocysteinemia Combined with Metabolic Syndrome and 
      Higher Prevalence of Stroke in Chinese Adults Who Have Elevated Blood Pressure.
PG  - e934100
LID - 10.12659/MSM.934100 [doi]
AB  - BACKGROUND Hyperhomocysteinemia (HHcy) and metabolic syndrome (MS) are 
      established cardiovascular risk factors of stroke and are frequently associated 
      with hypertension. However, studies on the association between HHcy combined with 
      MS and stroke risk in hypertensive patients were absent. MATERIAL AND METHODS In 
      14 059 selected participants with elevated blood pressure, we assessed the 
      prevalence of the MS and stroke. We defined HHcy as plasma total homocysteine >15 
      mumol/L. MS was defined according to the Chinese Diabetes Society (CDS) criterion. 
      Multivariable analysis was used to examine the association of HHcy or (and) MS 
      with stroke risk in different models. RESULTS The prevalence rates of HHcy and MS 
      were 49.96% and 42.21%, respectively. Patients with stroke had higher plasma 
      total homocysteine levels and a higher prevalence of MS (P<0.001). Multivariable 
      analyses indicated that HHcy and MS are independently associated with higher 
      prevalence of stroke (adjusted-odds ratio (OR): 1.36, 95% CI 1.17 to 1.58, 
      P<0.001; adjusted-OR: 1.68, 95% CI 1.44 to 1.96, P<0.001, respectively). Those 
      with combined HHcy and MS had higher odds of stroke than those with isolated HHcy 
      or MS (adjusted-OR: 1.78, 95% CI 1.47 to 2.15, P<0.001; adjusted-OR: 1.39, 95% CI 
      1.13 to 1.70, P=0.002, respectively). CONCLUSIONS HHcy combined with MS was 
      associated with higher prevalence of stroke in Chinese adults with elevated blood 
      pressure.
FAU - Hu, Feng
AU  - Hu F
AD  - Department of Cardiovascular Medicine, The Second Affiliated Hospital of Nanchang 
      University, Nanchang, Jiangxi, China (mainland).
AD  - Jiangxi Provincial Cardiovascular Disease Clinical Medical Research Center, 
      Nanchang, Jiangxi, China (mainland).
FAU - Yu, Shichao
AU  - Yu S
AD  - Department of General Practice Medicine, Tuo Chuan Town Health Center, Wuyuan, 
      Jiangxi, China (mainland).
FAU - Li, Juan
AU  - Li J
AD  - The College of Pharmacy, Nanchang University, Nanchang, Jiangxi, China 
      (mainland).
FAU - Zhou, Wei
AU  - Zhou W
AD  - Jiangxi Provincial Cardiovascular Disease Clinical Medical Research Center, 
      Nanchang, Jiangxi, China (mainland).
AD  - Center for Prevention and Treatment of Cardiovascular Diseases, The Second 
      Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China (mainland).
FAU - Wang, Tao
AU  - Wang T
AD  - Jiangxi Provincial Cardiovascular Disease Clinical Medical Research Center, 
      Nanchang, Jiangxi, China (mainland).
AD  - Center for Prevention and Treatment of Cardiovascular Diseases, The Second 
      Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China (mainland).
FAU - Huang, Xiao
AU  - Huang X
AD  - Department of Cardiovascular Medicine, The Second Affiliated Hospital of Nanchang 
      University, Nanchang, Jiangxi, China (mainland).
AD  - Jiangxi Provincial Cardiovascular Disease Clinical Medical Research Center, 
      Nanchang, Jiangxi, China (mainland).
AD  - Center for Prevention and Treatment of Cardiovascular Diseases, The Second 
      Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China (mainland).
FAU - Bao, Huihui
AU  - Bao H
AD  - Department of Cardiovascular Medicine, The Second Affiliated Hospital of Nanchang 
      University, Nanchang, Jiangxi, China (mainland).
AD  - Jiangxi Provincial Cardiovascular Disease Clinical Medical Research Center, 
      Nanchang, Jiangxi, China (mainland).
AD  - Center for Prevention and Treatment of Cardiovascular Diseases, The Second 
      Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China (mainland).
FAU - Cheng, Xiaoshu
AU  - Cheng X
AD  - Department of Cardiovascular Medicine, The Second Affiliated Hospital of Nanchang 
      University, Nanchang, Jiangxi, China (mainland).
AD  - Jiangxi Provincial Cardiovascular Disease Clinical Medical Research Center, 
      Nanchang, Jiangxi, China (mainland).
AD  - Center for Prevention and Treatment of Cardiovascular Diseases, The Second 
      Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China (mainland).
LA  - eng
PT  - Journal Article
DEP - 20220111
PL  - United States
TA  - Med Sci Monit
JT  - Medical science monitor : international medical journal of experimental and 
      clinical research
JID - 9609063
RN  - 0 (Biomarkers)
RN  - 0LVT1QZ0BA (Homocysteine)
SB  - IM
MH  - Aged
MH  - Biomarkers/blood
MH  - Blood Pressure Determination/methods/statistics & numerical data
MH  - China/epidemiology
MH  - Comorbidity
MH  - Correlation of Data
MH  - Female
MH  - Heart Disease Risk Factors
MH  - Homocysteine/*blood
MH  - Humans
MH  - *Hyperhomocysteinemia/blood/diagnosis/epidemiology
MH  - *Hypertension/diagnosis/epidemiology/metabolism
MH  - Male
MH  - *Metabolic Syndrome/blood/diagnosis/epidemiology
MH  - Prevalence
MH  - Risk Assessment/methods
MH  - *Stroke/diagnosis/epidemiology/metabolism/physiopathology
PMC - PMC8764874
COIS- Conflict of interest: None declared
EDAT- 2022/01/12 06:00
MHDA- 2022/03/15 06:00
PMCR- 2022/01/11
CRDT- 2022/01/11 06:26
PHST- 2022/01/11 06:26 [entrez]
PHST- 2022/01/12 06:00 [pubmed]
PHST- 2022/03/15 06:00 [medline]
PHST- 2022/01/11 00:00 [pmc-release]
AID - 934100 [pii]
AID - 10.12659/MSM.934100 [doi]
PST - epublish
SO  - Med Sci Monit. 2022 Jan 11;28:e934100. doi: 10.12659/MSM.934100.